The first NOAC with
a reversal agent
a reversal agent
YOUR FORESIGHT.
HIS FUTURE.
Pradaxa® (Dabigatran etexilate) is proven to effectively lower the risks of stroke, and gives you the assurance of reversibility with Praxbind® (Idarucizumab) in emergency situations.
publications
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- Dabigatran and Warfarin in Vitamin K Antagonist Naive and Experienced Cohorts With Atrial Fibrillation
- Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease
The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) - Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin
Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial - Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
- Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran
The RE-LY Trial - Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
- Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
An Analysis of the Randomized Evaluation of Long-Term Anticoagulant
Therapy (RE-LY) Trial - Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
- Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion
- Management and Outcomes of Major Bleeding during Treatment with Dabigatran or Warfarin
- Perioperative Management of Dabigatran: A Prospective Cohort Study
- Dabigatran Versus Warfarin
Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation - Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice
A Systematic Review and Meta-Analysis - Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin
- Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
- Dabigatran Etexilate
A New Oral Thrombin Inhibitor - Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
- Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation
- Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
- Idarucizumab
The Antidote for Reversal of Dabigatran - Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association
- Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation (Systematic Review and Meta-Analysis)
- Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab
- Using Dabigatran in Patients With Stroke
- Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
- Bleeding risk higher with rivaroxaban than dabigatran for stroke prevention, head-to-head trial shows
- Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
- Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
- Stroke prevention in AF: Of Asians and non-Asians
- Dabigatran Versus Warfarin (Effects on Ischemic and Hemorrhagic Strokes and Bleeding in Asians and Non-Asians With Atrial Fibrillation)
- Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score
- Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation (A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy)
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation (A Randomized Evaluation of Long-term Anticoagulation Therapy Trial Analysis)
- Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: A subgroup analysis of the RE-LY trial
- Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries - An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
- Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation
- Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
- Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
- Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin-K Oral Anticoagulants (RAF-NOACs) Study
- The Changing Landscape for Stroke Prevention in AF; Findings From the GLORIA-AF Registry Phase 2
- Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry)
- Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction
- Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes (ORBIT-AF Registry)
- Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants
- Risk of Recurrent Ischemic Stroke with Unintended Low-Dose Oral Anticoagulant Therapy and Optimal Timing of Review
- Comparative Effectiveness and Safety of Standard or Reduced Dose Dabigatran vs. Rivaroxaban in Nonvalvular Atrial Fibrillation
- Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study)
- Real‑world 2‑year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease
- Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
- Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation (The NAXOS Study)
- Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
- Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin-K Oral Anticoagulants (RAF-NOACs) Study
- Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
- Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
- Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study
- Clinical Guidelines on COVID-19 Vaccination in Malaysia
- Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL* protocol
- ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic [aka ESC Guidance COVID-19 Pandemic]
- Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry [aka HOPE COVID registry]
- The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia [aka Cancer and COVID in AF]
PC-MY-100482
Production date: Jan 2019
Production date: Jan 2019
What is Dabigatran etexilate (Pradaxa®)
Dabigatran etexilate (Pradaxa®) is a prescription blood thinner medicine that lowers the chance of blood clots forming in the body.
Dabigatran etexilate (Pradaxa®) is used to:
Dabigatran etexilate (Pradaxa®) is not for use in people with artificial (prosthetic) heart valves.
Dabigatran etexilate (Pradaxa®) is used to:
- Reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming and increase your risk of a stroke.
- Treat blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) and reduce the risk of them occurring again.
Dabigatran etexilate (Pradaxa®) is not for use in people with artificial (prosthetic) heart valves.
IMPORTANT SAFETY INFORMATION AND USE OF Dabigatran etexilate (Pradaxa®)
For people taking Dabigatran etexilate (Pradaxa®) for atrial fibrillation: Patients should not stop taking Dabigatran etexilate (Pradaxa®) without talking to the doctor who prescribed it. Discontinuation of Dabigatran etexilate (Pradaxa®) without doctor's advice increases risk of having a stroke. Dabigatran etexilate (Pradaxa®) may need to be stopped prior to surgery or a medical or dental procedure. Physician should inform patients when to stop taking Dabigatran etexilate (Pradaxa®) and when patients may start taking it again. If patients have to stop taking Dabigatran etexilate (Pradaxa®), physician may prescribe another medicine to help prevent a blood clot from forming.
As with all anticoagulants, Dabigatran etexilate (Pradaxa®) should be used with caution in conditions with an increased risk of bleeding. Bleeding can occur at any site during therapy with Dabigatran etexilate (Pradaxa®). It is contraindicated for patients who:
Caution should be taken when taking Dabigatran etexilate (Pradaxa®) if patients:
For pregnant patients or patients who plan to get pregnant, no clinical data on exposed pregnancies are available. The potential risks for humans is unknown. Patients should inform their doctors right away if they become pregnant during treatment. Pregnant patients should not be treated with Dabigatran etexilate (Pradaxa®) unless the expected benefit is greater than the risk.
For breastfeeding or patients planning to breastfeed, it is not known if Dabigatran etexilate (Pradaxa®) passes into the breast milk. As precaution, breast-feeding should be stopped.
Please see full prescribing information before prescribing.
Reference:
1. Prescribing information, Boehringer Ingelheim Malaysia
2. Medication guide, Pradaxa® USPI.
As with all anticoagulants, Dabigatran etexilate (Pradaxa®) should be used with caution in conditions with an increased risk of bleeding. Bleeding can occur at any site during therapy with Dabigatran etexilate (Pradaxa®). It is contraindicated for patients who:
- Currently have abnormal bleeding.
- Have ever had an allergic reaction to it
- Have had or plan to have a valve in your heart replaced
Caution should be taken when taking Dabigatran etexilate (Pradaxa®) if patients:
- Are 75 years old or older
- Have kidney problems
- Have stomach or intestine bleeding that is recent or keeps coming back or have a stomach ulcer
- Take other medicines that increase risk of bleeding, like aspirin products, non-steroidal anti-inflammatory drugs (NSAIDs) and other blood thinners
- Have kidney problems and take dronedarone or ketoconazole tablets
For pregnant patients or patients who plan to get pregnant, no clinical data on exposed pregnancies are available. The potential risks for humans is unknown. Patients should inform their doctors right away if they become pregnant during treatment. Pregnant patients should not be treated with Dabigatran etexilate (Pradaxa®) unless the expected benefit is greater than the risk.
For breastfeeding or patients planning to breastfeed, it is not known if Dabigatran etexilate (Pradaxa®) passes into the breast milk. As precaution, breast-feeding should be stopped.
Please see full prescribing information before prescribing.
Reference:
1. Prescribing information, Boehringer Ingelheim Malaysia
2. Medication guide, Pradaxa® USPI.